Neuroprotective effects of a nanocrystal formulation of sPLA2 inhibitor PX-18 in cerebral ischemia/reperfusion in gerbils

Brain Research

Volumn 1285, Issue , 2009, Pages 188-195

  Wang, Qun ^a   Sun, Albert Y ^a   Pardeike, Jana ^b   Müller, Rainer H ^b   Simonyi, Agnes ^a   Sun, Grace Y ^a  

^a University of Missouri   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Cerebral ischemia reperfusion; Delayed neuronal death; Glial activation; Inflammation; PX 18 nanocrystal; sPLA2 inhibitor

Indexed keywords

NANOCRYSTAL; PX 18; SECRETORY PHOSPHOLIPASE A2; SECRETORY PHOSPHOLIPASE A2 INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN ISCHEMIA; COMMON CAROTID ARTERY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DNA DAMAGE; DRUG FORMULATION; DRUG SOLUBILITY; ENZYME REGULATION; GERBIL; HEART INFARCTION; INFLAMMATION; MALE; MICROGLIA; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; TISSUE INJURY; TRANSIENT ISCHEMIC ATTACK;

ALKANESULFONIC ACIDS; ANIMALS; BRAIN; BRAIN ISCHEMIA; CELL DEATH; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GERBILLINAE; GLIOSIS; HIPPOCAMPUS; MALE; NANOPARTICLES; NERVE DEGENERATION; NEUROGLIA; NEUROPROTECTIVE AGENTS; OLEIC ACIDS; PHOSPHOLIPASES A2, SECRETORY; REPERFUSION INJURY; TREATMENT OUTCOME;

GERBILLINAE;

EID: 67651172765     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.06.022     Document Type: Article

References (59)

1. Adibhatla R.M., and Hatcher J.F. Secretory phospholipase A2 IIA is up-regulated by TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat. Brain Res. 1134 (2007) 199-205
2. Adibhatla R.M., and Hatcher J.F. Secretory phospholipase A(2) IIA is up-regulated by TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat. Brain Res. 1134 (2007) 199-205
3. Aktas Y., Andrieux K., Alonso M.J., Calvo P., Gursoy R.N., Couvreur P., and Capan Y. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int. J. Pharm. 298 (2005) 378-383
4. Aktas Y., Yemisci M., Andrieux K., Gursoy R.N., Alonso M.J., Fernandez-Megia E., Novoa-Carballal R., Quinoa E., Riguera R., Sargon M.F., Celik H.H., Demir A.S., Hincal A.A., Dalkara T., Capan Y., and Couvreur P. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem. 16 (2005) 1503-1511
5. Böhm B., Hildebrand G., Thünemann A.F., and Müller R.H. Preparation and physical properties of nanosuspensions (Dissocubes) of poorly soluble drugs. Controlled Release Society (1998) 956-957
6. Burke J.E., and Dennis E.A. Phospholipase A2 structure/function, mechanism and signaling. J. Lipid Res. (2009) 50 Suppl:S237-242
7. Camargo E.A., Ferreira T., Ribela M.T., de Nucci G., Landucci E.C., and Antunes E. Role of substance P and bradykinin in acute pancreatitis induced by secretory phospholipase A2. Pancreas 37 (2008) 50-55
8. DeCoster M.A., Lambeau G., Lazdunski M., and Bazan N.G. Secreted phospholipase A2 potentiates glutamate-induced calcium increase and cell death in primary neuronal cultures. J. Neurosci. Res. 67 (2002) 634-645
9. Franson R.C., and Rosenthal M.D. Oligomers of prostaglandin B1 inhibit in vitro phospholipase A2 activity. Biochim. Biophys. Acta 1006 (1989) 272-277
10. Franson R.C., and Rosenthal M.D. PX-52, A novel inhibitor of 14 kDa secretory and 85 kDa cytosolic phospholipases A2. Adv. Exp. Med. Biol. 400A (1997) 365-373
11. Gabryel B., Chalimoniuk M., Stolecka A., and Langfort J. Activation of cPLA2 and sPLA2 in astrocytes exposed to simulated ischemia in vitro. Cell Biol. Int. 31 (2007) 958-965
12. Gao X., Tao W., Lu W., Zhang Q., Zhang Y., Jiang X., and Fu S. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 27 (2006) 3482-3490
13. Gessner A., Olbrich C., Schroder W., Kayser O., and Muller R.H. The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int. J. Pharm. 214 (2001) 87-91
14. Goppert T.M., and Muller R.H. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Target 13 (2005) 179-187
15. Hara A., Niwa M., Iwai T., Nakashima M., Bunai Y., Uematsu T., Yoshimi N., and Mori H. Neuronal apoptosis studied by a sequential TUNEL technique: a method for tract-tracing. Brain Res. Brain Res. Protoc. 4 (1999) 140-146
16. Ibeas E., Fuentes L., Martin R., Hernandez M., and Nieto M.L. Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis. Cardiovasc. Res. 81 (2009) 54-63
17. Ishibashi N., Prokopenko O., Reuhl K.R., and Mirochnitchenko O. Inflammatory response and glutathione peroxidase in a model of stroke. J. Immunol. 168 (2002) 1926-1933
18. Keck C.M., and Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 62 (2006) 3-16
19. Kimura-Matsumoto M., Ishikawa Y., Komiyama K., Tsuruta T., Murakami M., Masuda S., Akasaka Y., Ito K., Ishiguro S., Morita H., Sato S., and Ishii T. Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis 196 (2008) 81-91
20. Ko Y.T., Bhattacharya R., and Bickel U. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J. Control. Release 133 (2009) 230-237
21. Kolko M., DeCoster M.A., de Turco E.B., and Bazan N.G. Synergy by secretory phospholipase A2 and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. J. Biol. Chem. 271 (1996) 32722-32728
22. Kolko M., Bruhn T., Christensen T., Lazdunski M., Lambeau G., Bazan N.G., and Diemer N.H. Secretory phospholipase A2 potentiates glutamate-induced rat striatal neuronal cell death in vivo. Neurosci. Lett. 274 (1999) 167-170
23. Kolko M., de Turco E.B., Diemer N.H., and Bazan N.G. Secretory phospholipase A2-mediated neuronal cell death involves glutamate ionotropic receptors. NeuroReport 13 (2002) 1963-1966
24. Krijnen P.A., Meischl C., Nijmeijer R., Visser C.A., Hack C.E., and Niessen H.W. Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction. Cardiovasc. Hematol. Disord. Drug Targets 6 (2006) 113-123
25. Lauritzen I., Heurteaux C., and Lazdunski M. Expression of group II phospholipase A2 in rat brain after severe forebrain ischemia and in endotoxic shock. Brain Res. 651 (1994) 353-356
26. Leitinger N., Watson A.D., Hama S.Y., Ivandic B., Qiao J.H., Huber J., Faull K.F., Grass D.S., Navab M., Fogelman A.M., de Beer F.C., Lusis A.J., and Berliner J.A. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1291-1298
27. Lin T.N., Wang Q., Simonyi A., Chen J.J., Cheung W.M., He Y.Y., Xu J., Sun A.Y., Hsu C.Y., and Sun G.Y. Induction of secretory phospholipase A2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain. J. Neurochem. 90 (2004) 637-645
28. Mallat Z., Benessiano J., Simon T., Ederhy S., Sebella-Arguelles C., Cohen A., Huart V., Wareham N.J., Luben R., Khaw K.T., Tedgui A., and Boekholdt S.M. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1177-1183
29. Masuda S., Murakami M., Ishikawa Y., Ishii T., and Kudo I. Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues. Biochim. Biophys. Acta 1736 (2005) 200-210
30. Meyer M.C., Rastogi P., Beckett C.S., and McHowat J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr. Pharm. Des. 11 (2005) 1301-1312
31. Meyer M.C., Rastogi P., Beckett C.S., and McHowat J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr. Pharm. Des. 11 (2005)
32. Molloy G.Y., Rattray M., and Williams R.J. Genes encoding multiple forms of phospholipase A2 are expressed in rat brain. Neurosci. Lett. 258 (1998) 139-142
33. Möschwitzer, J., Lemke, A., 2005. Method for the gentle production of ultrafine particle suspensions. Vol., ed.^eds. 017 777.8 DE 10.
34. Möschwitzer J., and Müller R.H. New method for the effective production of ultrafine drug nanocrystals. J. Nanosci. Nanotechnol. 6 (2006) 3145-3153
35. Moses G.S.D., Jensen M.D., Lue L.F., Walker D.G., Sun A.Y., Simonyi A., and Sun G.Y. Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. J. Neuroinflammation 3 (2006) 1-11
36. Muller R.H., and Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113 (2004) 151-170
37. Muller R.H., and Keck C.M. Drug delivery to the brain-realization by novel drug carriers. J. Nanosci. Nanotechnol. 4 (2004) 471-483
38. Müller R.H., and Peters K. Nanosuspension for the formulation of poorly soluble drugs 1. Preparation by a size-reduction technique. Int. J. Pharm. 160 (1997) 229-237
39. Müller R.H., and Akkar A. Drug nanocrystals of poorly solible drugs. Encycl. Nanosci. Nanotechnol. 2 (2004) 627-638
40. Müller R.H., and Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113 (2004) 151-170
41. Müller R.H., Runge S., Ravelli V., Mehnert W., Thunemann A.F., and Souto E.B. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 317 (2006) 82-89
42. Murakami M., and Kudo I. Phospholipase A2. J. Biochem. 131 (2002) 285-292
43. Murakami M., and Kudo I. Secretory phospholipase A2. Biol. Pharm. Bull. 27 (2004) 1158-1164
44. Muralikrishna Adibhatla R., and Hatcher J.F. Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic. Biol. Med. 40 (2006) 376-387
45. Nijmeijer R., Willemsen M., Meijer C.J., Visser C.A., Verheijen R.H., Gottlieb R.A., Hack C.E., and Niessen H.W. Type II secretory phospholipase A2 binds to ischemic flip-flopped cardiomyocytes and subsequently induces cell death. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H2218-H2224
46. Nijmeijer R., Meuwissen M., Krijnen P.A., van der Wal A., Piek J.J., Visser C.A., Hack C.E., and Niessen H.W. Secretory type II phospholipase A2 in culprit coronary lesions is associated with myocardial infarction. Eur. J. Clin. Invest. 38 (2008) 205-210
47. Oslund R.C., Cermak N., and Gelb M.H. Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. J. Med. Chem. 51 (2008) 4708-4714
48. Rastogi P., Beckett C.S., and McHowat J. Prostaglandin production in human coronary artery endothelial cells is modulated differentially by selective phospholipase A(2) inhibitors. Prostaglandins Leukot. Essent. Fat. Acids 76 (2007) 205-212
49. Rodriguez De Turco E.B., Jackson F.R., DeCoster M.A., Kolko M., and Bazan N.G. Glutamate signalling and secretory phospholipase A2 modulate the release of arachidonic acid from neuronal membranes. J. Neurosci. Res. 68 (2002) 558-567
50. Sauer I., Dunay I.R., Weisgraber K., Bienert M., and Dathe M. An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. Biochemistry 44 (2005) 2021-2029
51. Schmued L.C., Albertson C., and Slikker Jr. W. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 751 (1997) 37-46
52. Smart B.P., Pan Y.H., Weeks A.K., Bollinger J.G., Bahnson B.J., and Gelb M.H. Inhibition of the complete set of mammalian secreted phospholipases A(2) by indole analogues: a structure-guided study. Bioorg. Med. Chem. 12 (2004) 1737-1749
53. Sun G.Y., Xu J., Jensen M.D., and Simonyi A. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid Res. 45 (2004) 205-213
54. Tietge U.J., Pratico D., Ding T., Funk C.D., Hildebrand R.B., Van Berkel T., and Van Eck M. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J. Lipid Res. 46 (2005) 1604-1614
55. Touaibia M., Djimde A., Cao F., Boilard E., Bezzine S., Lambeau G., Redeuilh C., Lamouri A., Massicot F., Chau F., Dong C.Z., and Heymans F. Inhibition of secreted phospholipase A2. 4-glycerol derivatives of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one with broad activities. J. Med. Chem. 50 (2007) 1618-1626
56. Wang Q., Xu J., Rottinghaus G.E., Simonyi A., Lubahn D., Sun G.Y., and Sun A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 958 (2002) 439-447
57. Yagami T., Ueda K., Asakura K., Hata S., Kuroda T., Sakaeda T., Takasu N., Tanaka K., Gemba T., and Hori Y. Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis. Mol. Pharmacol. 61 (2002) 114-126
58. Yagami T., Ueda K., Asakura K., Nakazato H., Hata S., Kuroda T., Sakaeda T., Sakaguchi G., Itoh N., Hashimoto Y., and Hori Y. Human group IIA secretory phospholipase A2 potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels in cultured rat cortical neurons. J. Neurochem. 85 (2003) 749-758
59. Yagami T., Ueda K., Hata S., Kuroda T., Itoh N., Sakaguchi G., Okamura N., Sakaeda T., and Fujimoto M. S-2474, a novel nonsteroidal anti-inflammatory drug, rescues cortical neurons from human group IIA secretory phospholipase A(2)-induced apoptosis. Neuropharmacology 49 (2005) 174-184